Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review.


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 17 08 2020
revised: 01 10 2020
accepted: 14 10 2020
pubmed: 20 1 2021
medline: 14 4 2022
entrez: 19 1 2021
Statut: ppublish

Résumé

The current pathological tumour-node-metastasis (pTNM) classification for upper tract urothelial carcinoma (UTUC) does not include any risk stratification of pT3 renal pelvicalyceal tumours. To assess the prognostic impact of pT3 subclassification in a multicentre cohort of patients with UTUC of the renal pelvicalyceal system undergoing radical nephroureterectomy (RNU). Data from all consecutive patients treated with RNU for pT3 renal pelvicalyceal UTUC at 14 French centres from 1995 to 2013 were reviewed retrospectively. A central pathology review (CPR) was used to stratify pT3 patients into those with infiltration of the renal parenchyma on a microscopic level (pT3a) versus those with infiltration of the renal parenchyma visible on gross inspection of the resection specimen and/or invasion of peripelvic fat (pT3b). Inverse probability weighting (IPW)-adjusted Cox regression analyses were used to compare recurrence-free survival (RFS) and cancer-specific survival (CSS) between pT3a and pT3b patients. Overall, 202 patients were included and further stratified into pT3a (n = 98; 48.5%) and pT3b (n = 104; 51.5%) subgroups. Median time to follow-up in the weighted population was 68 (interquartile range, 50-95) mo. In IPW-adjusted Cox regression analyses, pT3b versus pT3a substage was associated with a significant adverse effect on RFS (hazard ratio [HR] = 2.02; 95% confidence interval [CI] = [1.36-3.01]; p < 0.001) and CSS (HR = 1.84; 95% CI = [1.20-2.82]; p = 0.005). The study is limited by its retrospective design. Using IPW-adjusted analyses after the CPR, we observed that RNU patients with pT3b renal pelvicalyceal UTUC had adverse prognosis as compared with those with pT3a disease. As such, this subclassification could help refine the current pTNM system for UTUC. In this report, we looked at the prognostic interest of stratifying patients with pT3 renal pelvicalyceal upper tract urothelial carcinoma based on the extent of local invasion. We found that those with extensive infiltration (pT3b) had adverse prognosis as compared with those with limited infiltration (pT3a). This information could be provided on pathology reports to further guide clinical decision making.

Sections du résumé

BACKGROUND BACKGROUND
The current pathological tumour-node-metastasis (pTNM) classification for upper tract urothelial carcinoma (UTUC) does not include any risk stratification of pT3 renal pelvicalyceal tumours.
OBJECTIVE OBJECTIVE
To assess the prognostic impact of pT3 subclassification in a multicentre cohort of patients with UTUC of the renal pelvicalyceal system undergoing radical nephroureterectomy (RNU).
DESIGN, SETTING, AND PARTICIPANTS METHODS
Data from all consecutive patients treated with RNU for pT3 renal pelvicalyceal UTUC at 14 French centres from 1995 to 2013 were reviewed retrospectively.
INTERVENTION METHODS
A central pathology review (CPR) was used to stratify pT3 patients into those with infiltration of the renal parenchyma on a microscopic level (pT3a) versus those with infiltration of the renal parenchyma visible on gross inspection of the resection specimen and/or invasion of peripelvic fat (pT3b).
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS METHODS
Inverse probability weighting (IPW)-adjusted Cox regression analyses were used to compare recurrence-free survival (RFS) and cancer-specific survival (CSS) between pT3a and pT3b patients.
RESULTS AND LIMITATIONS CONCLUSIONS
Overall, 202 patients were included and further stratified into pT3a (n = 98; 48.5%) and pT3b (n = 104; 51.5%) subgroups. Median time to follow-up in the weighted population was 68 (interquartile range, 50-95) mo. In IPW-adjusted Cox regression analyses, pT3b versus pT3a substage was associated with a significant adverse effect on RFS (hazard ratio [HR] = 2.02; 95% confidence interval [CI] = [1.36-3.01]; p < 0.001) and CSS (HR = 1.84; 95% CI = [1.20-2.82]; p = 0.005). The study is limited by its retrospective design.
CONCLUSIONS CONCLUSIONS
Using IPW-adjusted analyses after the CPR, we observed that RNU patients with pT3b renal pelvicalyceal UTUC had adverse prognosis as compared with those with pT3a disease. As such, this subclassification could help refine the current pTNM system for UTUC.
PATIENT SUMMARY RESULTS
In this report, we looked at the prognostic interest of stratifying patients with pT3 renal pelvicalyceal upper tract urothelial carcinoma based on the extent of local invasion. We found that those with extensive infiltration (pT3b) had adverse prognosis as compared with those with limited infiltration (pT3a). This information could be provided on pathology reports to further guide clinical decision making.

Identifiants

pubmed: 33463527
pii: S2405-4569(20)30288-1
doi: 10.1016/j.euf.2020.10.004
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1075-1083

Informations de copyright

Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Thomas Seisen (T)

Sorbonne University, GRC 5 Predictive ONCO-URO, AP-HP, Urology, Pitie-Salpetriere Hospital, F-75013 PARIS, France.

Andrea Mari (A)

Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.

Riccardo Campi (R)

Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.

Benoit Peyronnet (B)

Department of Urology, Rennes University Hospital, Rennes, France.

Karim Bensalah (K)

Department of Urology, Rennes University Hospital, Rennes, France.

Nathalie Rioux-Leclercq (N)

Department of Pathology, Rennes University Hospital, Rennes, France.

Christian Pfister (C)

Department of Urology, Rouen University Hospital, Rouen, France.

Françoise Gobet (F)

Department of Pathology, Rouen University Hospital, Rouen, France.

Alexandre De La Taille (A)

Department of Urology, Henri Mondor Hospital, Créteil, France.

Yves Allory (Y)

Department of Pathology, Henri Mondor Hospital, Créteil, France.

Evanguelos Xylinas (E)

Department of Urology, Cochin Hospital, Paris, France.

Yann Neuzillet (Y)

Department of Urology, Foch Hospital, Surenes, France.

Camelia Radulescu (C)

Department of Pathology, Foch Hospital, Surenes, France.

Jean-Luc Descotes (JL)

Department of Urology, Grenoble University Hospital, Grenoble, France.

Géraldine Saada-Sebag (G)

Department of Pathology, Grenoble University Hospital, Grenoble, France.

Jacques Irani (J)

Department of Urology, Poitier University Hospital, Poitier, France.

Céline Delpech-Debiais (C)

Department of Pathology, Poitier University Hospital, Poitier, France.

Pierre Bigot (P)

Department of Urology, Angers University Hospital, Angers, France.

Caroline Eymerit (C)

Department of Pathology, Angers University Hospital, Angers, France.

Sebastien Crouzet (S)

Department of Urology, Edouard Henriot Hospital, Lyon, France.

Florence Mege-Lechevallier (F)

Department of Pathology, Edouard Henriot Hospital, Lyon, France.

Alain Ruffion (A)

Department of Urology, Lyon Sud University Hospital, Pierre Bénite, France.

Myriam Decaussin-Petrucci (M)

Department of Pathology, Lyon Sud University Hospital, Pierre Bénite, France.

Stéphane Droupy (S)

Department of Urology, Nîmes University Hospital, Nîmes, France.

Pascal Roger (P)

Department of Pathology, Nîmes University Hospital, Nîmes, France.

Xavier Durand (X)

Department of Urology, Val-de-Grâce Hospital, Paris, France.

Philippe Camparo (P)

Department of Pathology, Val-de-Grâce Hospital, Paris, France.

Olivier Cussenot (O)

Department of Urology, Tenon Hospital, Paris, France.

Eva Compérat (E)

Department of Pathology, Tenon Hospital, Paris, France.

Morgan Rouprêt (M)

Sorbonne University, GRC 5 Predictive ONCO-URO, AP-HP, Urology, Pitie-Salpetriere Hospital, F-75013 PARIS, France. Electronic address: morgan.roupret@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH